PJSC PROMOMED is a leading innovative biopharmaceutical company with the potential for significant growth in promising segments of the pharmaceutical market. The Company's structure includes its own unique world-class R&D center and a high–tech enterprise, the Biochemist plant. Thanks to this, PROMOMED implements the concept of a full production cycle "from Idea to Molecule, from Molecule to Patient", promptly responds to the current needs of the industry, and also implements the latest technologies to create innovative medicines.

The company develops a diversified portfolio of more than 360 medicines in the most promising therapeutic areas, such as Endocrinology, overweight treatment, Oncology, Neurology, Autoimmune diseases, Acute and chronic pain, as well as a number of others.

PROMOMED distributes to the budget and commercial market segments. More than 60% of the products produced by the Company are included in the state list of vital and essential medicines (VED).

Innovative drugs are drugs with a new molecule or a fundamentally new or improved mechanism of action. Their development involves a full cycle of research: from the search for a molecule and preclinical trials to the passage of all stages of clinical research. Such drugs are usually original, they are protected by patents and require significant early investments, but at the same time they provide breakthrough results in the treatment of various diseases, including the possibility of treating previously intractable diseases.

Generics are biequivalent drugs of original medicines that are put on the market after the expiration of patent protection. They contain the same active molecule, but are often developed using a different technology, which significantly reduces the cost of therapy and increases its accessibility to patients.

However, in modern pharmaceuticals, innovation is not always limited to the creation of a completely new molecule. In some cases, innovation can be formed due to deep scientific and technological refinement of known molecules - improving the efficiency and safety profile, the form of release, the method of delivery or production technology. Formally, such drugs may belong to generics, but in essence they are next-in-class solutions and create new therapeutic opportunities.

The strategic focus of PJSC PROMOMED is the development, production and commercialization of innovative medicines, including both original drugs and advanced solutions based on known molecules.
At the same time, PROMOMED maintains and develops the basic generic portfolio, ensuring the country's drug safety and replacing outgoing foreign manufacturers, but innovation is at the heart of the Company's long-term strategy.

"First-in-class" is a drug with a fundamentally new mechanism of action. Such drugs set new standards for therapy and have a unique effect in treatment.

"Next-in-class" is an innovative drug in an existing class that offers improved performance compared to existing products: greater efficacy, an improved safety profile, and/or a convenient form of use.

At the same time, both classes of drugs are innovative.

PROMOMED combines both approaches by developing first–in-class revolutionary drugs and offering improved medicines to millions of patients.

PROMOMED operates in a large and steadily growing pharmaceutical market. According to Strategy Partners forecasts, by 2032 the volume of the Russian pharmaceutical market will increase to 4.7 trillion rubles, with an average annual growth rate of about 8.7%. More than 50% of its volume is devoted to the treatment of oncological and endocrinological diseases, which are strategic for the Group. It is these areas that are in the greatest need of innovation and high-tech therapeutic solutions today.

The prospects of the chosen strategic directions are confirmed by market data. Strategy Partners estimates that the market volume in the overweight and diabetes segment will increase to RUB 100 billion by 2032. with an average annual growth rate of about 29%. The segment of targeted therapy for aggressive forms of cancer will reach 155 billion rubles by 2032, demonstrating an average annual growth of 7%.
An additional structural driver of the global and Russian pharmaceutical market growth is the transition to biotechnological drugs. The development and production of such drugs is one of the key areas of PROMOMED's development. According to Strategy Partners forecasts, the Russian biopharmaceutical market will grow to 2.4 billion rubles by 2032. with an average annual growth rate of about 36%.

At the same time, the Russian pharmaceutical market is characterized by a high degree of fragmentation: the largest player occupies less than 6% of its total volume. By the end of 2025, PROMOMED entered the TOP 6 Russian companies in the domestic pharmaceutical market with a share of 3.8%.

The growth of the pharmaceutical market is due to a combination of factors:

Demographic trends An increase in average life expectancy implies an expansion of the cohorts of the population in need of pharmaceutical care, and an elongation of all life phases implies a prolonged need for treatment of chronic diseases.
• The increase in the prevalence of diseases is increasing the number of patients with obesity, diabetes, cancer, autoimmune and infectious diseases, which creates a steady long-term demand for appropriate therapy.
• Government initiatives and support measures The implementation of national projects and measures to support domestic manufacturers (840 billion rubles will be allocated to fight cancer alone in 2025-2030 as part of the national project "Long and active Life") provide additional demand for sought-after and effective solutions. 
• The development of innovations and technologies, the active introduction of biotechnologies, the expansion of the use of targeted drugs, RNA platforms and the use of artificial intelligence accelerate drug development, increase the effectiveness of therapy and expand the treatment options for previously intractable diseases.

PROMOMED implements a strategy with a focus on the development, production and commercialization of innovative drugs. The strategy is based on the formation of our own portfolio of drugs in the fastest growing therapeutic areas.

The key objectives of the PROMOMED strategy are to increase sales to 240 billion rubles by 2032 and consolidate its position in the TOP 3 innovative fast-growing biopharmaceutical companies in Russia.

Key priorities of the strategy:

• Expanding the horizons of therapy through innovative drugs — according to Strategy Partners, PROMOMED should occupy a 35% share of the new drugs market by 2032. The focus on the development and production of innovative and biotechnological drugs allows us to systematically outpace the market, create affordable high-tech therapies for the healthcare system, and expand treatment options for chronic and previously intractable diseases. 
• The growth rate of the basic portfolio is outpacing the market — according to the Company's forecasts, the portfolio of basic drugs will grow with a growth rate of 16% until 2032. This will be possible due to the deepening of the presence in socially significant therapeutic areas, the replacement of outgoing foreign manufacturers and the contribution to ensuring national drug safety through a full-cycle strategy, an important feature of which is its own synthesis of APIs.
• Maintaining high standards of operational efficiency is the Company's long—term goal of improving EBITDA margin to 55%. The company consistently scales and adapts the operating model as production expands. At the same time, an integral feature of the strategy, which ensures special stability and predictability, is the deep digitalization of internal processes using AI, as well as well-established processes of S&OP¹ and project management.
  
  ¹ - Sales and operations planning

PROMOMED's production facilities are concentrated on its own full-cycle high-tech sites, the key of which are the Biochemik and Berakhim plants located in Russia.

The Company's flagship production asset is the Biochemik plant in Saransk, one of the largest and most technologically equipped pharmaceutical production complexes in the country. The site provides a full cycle of drug production: from the synthesis of active pharmaceutical substances, including chemical and biotechnological APIs, to the production of finished dosage forms in accordance with international GMP standards.
A complementary element of the production infrastructure is the Berakhim plant, specializing in the production of active pharmaceutical substances and chemical components, which allows the Company to reduce dependence on external suppliers, control production costs and ensure the sustainability of supply chains.

The combination of these capacities forms a full-cycle production platform that ensures technological independence and the ability to market and accelerate the commercialization of drugs.

PROMMED's dividend policy reflects the current stage of the Company's development while maintaining a high level of investment in R&D and at the same time sets transparent and predictable benchmarks for dividend growth as the business scales. At the same time, PROMOMED adheres to strict financial discipline, ensuring a balance between investments in development and the return of capital to shareholders.

The amount of dividend payments is directly linked to the debt burden (Net debt¹ / adjusted EBITDA LTM² at the end of the reporting period):

At BH / cor. EBITDA LTM at the end of the reporting period:

• Below 1.0x – at least 50% of adjusted net income³

• 1.0x – 2.0x – at least 25% of adjusted net income

• 2.0x – 2.5x – at least 15% of adjusted net income

• Above 2.5x – the issue of payment of dividends by decision of the Board of Directors

[1] Net debt is an indicator of net debt, the calculation procedure of which is equal to the total amount owed on loans, borrowings and lease obligations, net of cash and cash equivalents, as well as short–term bank deposits at each reporting date.

[3] Net profit for the period adjusted for the amount of capitalized expenses in respect of fixed assets and IA (payments in connection with the acquisition, creation, modernization, reconstruction and preparation for use of fixed assets and payments in connection with the acquisition and creation of intangible assets) and depreciation on capitalized expenses in respect of fixed assets and NMA;